Skip to main content
Premium Trial:

Request an Annual Quote

Novartis' Genoptix Licenses Trovagene Marker for AML Services

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted to Genoptix a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.

Genoptix, a Novartis company, will pay Trovagene upfront and royalty payments. Further terms of the deal were not disclosed.

Trovagene holds the exclusive worldwide license to the patent around NPM1 and has granted sublicenses to offer mutation analysis of the protein as a laboratory service for the diagnosis and monitoring of patients with AML to Quest Diagnostics, Laboratory Corporation of America, Münchner Leukamielabor in Germany, Skyline Labs in the Netherlands, and others.

NPM1 mutation testing is recommended by the national Comprehensive Cancer Network, which sets clinical treatment standards for a number of cancers, Trovagene said.

The San Diego-based molecular diagnostics firm also has deals to manufacture and sell NPM1 mutation kits to Asuragen and Ipsogen, which was acquired by Qiagen last year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.